The aim of this article is to provide a comprehensive and concise review of existing literature and findings about negative symptoms associated with the diagnosis of schizophrenia. Significant progress has been made regarding the awareness of negative symptoms associated with schizophrenia. Given this progress, psychiatric nurses shouldfind it useful to have information about how to provide state-of-the-art care and clinical interventionsfor treatment of negative symptoms. Acquiring this information requires some understanding of etiologicfactors, assessment, and use of contemporary medications to attend to the disabling effects of negative symptoms.
Get full access to this article
View all access options for this article.
References
1.
Addington, D., Addington, J., & Schissel, B. (1990). A depression scale for schizophrenia. Schizophrenia Research, 3, 247-251.
2.
American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3.
Ames, D., Wirshing, W. C., & Marder, S. R. (1996). Advances in antipsychotic pharmacotherapy: Clozapine, risperidone, and beyond. Essential Psychopharmacology, 1, 5-26.
4.
Andreasen, N. C. (1982). Negative symptoms in schizophrenia: Definition and reliability. Archives of General Psychiatry, 39, 784-788.
5.
Andreasen, N. C. (1984). Thse Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
6.
Andreasen, N. C. (1989). The Scale for Negative Symptoms (SANS): Conceptual and theoretical foundations. British Journal of Psychiatry, 155 (suppl. 7), 49-58.
7.
Andreasen, N. C., Arndt, S., Alliger, R., Miller, D., & Flaum, M. (1995). Symptoms of schizophrenia: Methods, meaning, and mechanisms. Archives of General Psychiatry, 52, 49-58.
8.
Arndt, S., Andreasen, N. C., Flaum, M., Miller, D., & Nopoulos, P. (1995). A longitudinal study of symptom dimension in schizophrenia: Predictions and patterns of change. Archives of General Psychiatry, 52, 352-360.
9.
Breier, A., Schreiber, J. L., Dyer, J., & Pickar, D. (1991). Course of illness and predictors of outcome in chronic schizophrenia. British Journal of Psychiatry, 161 (suppl. 18), 38-43.
10.
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. W., & Wong, D. T. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology, 14, 87-96.
11.
Carpenter, W. T., Heinrichs, D. W., & Alphs, L. D. (1985). Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440-452.
12.
Coffman, J. A. (1989). Computer tomography in psychiatry. In N. C. Andreasen (Eds.), Brain imaging: Applications in psychiatry (pp. 1-65). Washington, DC: American Psychiatric Press.
13.
Crow, T. J. (1980). Molecular pathology of schizophrenia: More than one disease process? British Journal of Psychiatry, 280, 66-68.
14.
Honigfeld, G., & Patin, J. (1990). A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry, 41, 882-885.
15.
Hyttel, J., Nielsen, J. B., & Nowak, G. (1992). The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radio receptor binding studies). Journal of Neural Transmitter and General Section, 89, 61-69.
16.
Jibson, M. D., & Tandon, R. (1995). The negative symptoms of schizophrenia. Directions in Psychiatry, 15, 1-8.
17.
Kandel, E. R., Schwartz, J. H., & Jessell, T. M. (1991). Principles of neural science (3rd ed.). New York: Elsevier.
18.
Kane, J., Honigfeld, G., Singer, J., Meltzer, H., & Clozaril Collaborative Study Group (1988). Clozapine for the treatment-resistant schizophrenia: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
19.
Kapur, S., & Remington, G. (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
20.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
21.
Kay, S. R., Fiszbein, A., Vital-Herne, M., & Fuentes, L. S. (1990). The Positive and Negative Syndrome Scale-Spanish adaptation. Journal of Nervous and Mental Disease, 178, 510-517.
22.
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1989). The Positive and Negative Syndrome Scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155 (suppl. 7), 59-65.
23.
Lieberman, J. A. (1996). Pharmacotherapy for patients with firstepisode, acute and refractory schizophrenia. Psychiatric Annals, 26, 515-518.
24.
Littrell, K., Peabody, C. D., & Littrell, S. H. (1996). Olanzapine: A new atypical antipsychotic. Journal of Psychosocial Nursing, 34 (8), 41-46.
Marder, S. R., & Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
27.
McGlashan, T. H., & Fenton, W. S. (1992). The positive-negative distinction in schizophrenia: Review of natural history validators. Archives of General Psychology, 49, 63-72.
28.
Meltzer, H. Y. (1996). Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review. British Journal of Psychiatry, 168 (suppl. 29), 23-31.
29.
Meltzer, H. Y., & Fibiger, H. C. (1996). Olanzapine: A new atypical antipsychotic drug. Neuropsychopharmacology, 14, 83-85.
30.
Mortimer, A. M., Lund, C. E., & McKenna, P. J. (1990). The positive:negative dichotomy in schizophrenia. British Journal of Psychiatry, 157, 41-49.
31.
Moscarelli, M., Maffei, C., Cesana, B. M., Boato, P., Farma, T., Grilli, A., Lingiardi, V., & Cazzullo, C. L. (1987). An international perspective on assessment of negative and positive symptoms in schizophrenia. American Journal of Psychiatry, 144, 1595-1598.
32.
Mueser, K. T., Sayers, S. L., Schooler, N. R., Mance, R. M., & Hass, G. L. (1994). A multisite investigation of the reliability of the scale for the assessment of negative symptoms. American Journal of Psychiatry, 151, 1453-1462.
33.
Peralta, V., & Cuesta, M. J. (1996). Symptoms of the schizophrenic negative syndrome. British Journal of Psychiatry, 169, 209-212.
34.
Peralta, V., de Leon, J., & Cuesta, M. J. (1992). Are there more than two syndromes in schizophrenia? British Journal of Psychiatry, 161, 335-343.
35.
Pickar, D. (1995, May). Towards a new generation of antipsychotic drugs. In J. Gorman (Chair), Progress in Psychosis. Symposium conducted at the American Psychiatric Association Annual Meeting, Miami, FL.
36.
Rifkin, A. (1992). Differentiating akinesia, depression, and negative symptoms. Current Approacbes to Psychoses: Diagnosis and Management, 1 (5), 2-4.
37.
Ring, N., Tantum, D., Montague, L., & Morris, J. (1991). Negative symptoms in chronic schizophrenia: Relationship to duration of illness. British Journal of Psychiatry, 159, 495-499.
38.
Robinson, A. L., Heaton, R. K., Lehman, R. A. W., & Stilson, D. W. (1980). The utility of the Wisconsin Card Sorting Test in detecting and localizing frontal lobe lesions. Journal of Consulting and Clinical Psychology, 48, 605-614.
39.
Sass, H. (1989). The historical evolution of the concept of negative symptoms in schizophrenia. British Journal of Psychiatry, 155 (suppl. 7), 26-31.
40.
Simpson, G. M., & Angus, J. W. S. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212 (Suppi), 11-19.
41.
Stefanis, C. N. (1990). On the concept of schizophrenia. In C. N. Kales & J. A. Stefanis (Eds.), Recent advances in schizophrenia (pp. 25-57). New York: Springer-Verlag.
42.
Strauss, J. S., Carpenter, W. T., & Bartko, J. J. (1974). Toward an understanding of symptom picture considered characteristic of schizophrenia: Its description, precursors and outcome. Schizophrenia Bulletin, 11, 61-69.
43.
Syvalahti, E. K. G. (1994). Biological factors in schizophrenia: Structural and functional aspects. British Journal of Psychiatry, 164 (suppl. 23), 9-14.
44.
Van Kammen, D. P., McEvoy, J. P., Targum, S. D., Kardatzke, D., Sebree, T. B., & Sertindole Study Group (1996). A randomized, controlled dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology, 124, 168-175.
45.
Weinberger, D. R., Aloia, M. S., Goldberg, T. E., & Berman, K. F. (1994). The frontal lobes and schizophrenia. Journal of Neuropsychiatry, 6, 419-427.
46.
Wolkin, A., Sanfilipo, M., Wolf, A. P., Angrist, B., Brodie, J. D., & Rotrosen, J. (1992). Negative symptoms and hypofrontality in chronic schizophrenia. Archives of General Psychiatry, 49, 959-965.
47.
Zubin, J. (1985). Negative symptoms: Are they indigenous to schizophrenia? Schizophrenia Bulletin, 11, 461-469.
